Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial.
Fiche publication
Date publication
avril 2024
Journal
Addiction (Abingdon, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TROJAK Benoît
Tous les auteurs :
Aubin HJ, Berlin I, Guiraud J, Bruhwyler J, Batel P, Perney P, Trojak B, Bendimerad P, Guillou M, Bisch M, Grall-Bronnec M, Labarrière D, Delsart D, Questel F, Moirand R, Bernard P, Trovero F, Pham HP, Tassin JP, Puech A
Lien Pubmed
Résumé
Pre-clinical studies suggest that the simultaneous blockade of the α1b and 5HT2A receptors may be effective in reducing alcohol consumption. This study aimed to assess the efficacy and safety of prazosin (α1b blocker) and cyproheptadine (5HT2A blocker) combination in decreasing total alcohol consumption (TAC) in alcohol use disorder (AUD).
Mots clés
Alcohol reduction, alcohol use disorder, cyproheptadine, prazosin, randomized controlled trial, risk drinking level
Référence
Addiction. 2024 04 10;: